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Abstract Residual confounding, after adjustment for age,
is the major criticism of observational studies on breast
cancer screening effectiveness. We developed realistic
scenarios for the prevalence and strength of risk factors on
screened and not screened groups, and explored the impact
of residual confounding bias. Our results demonstrate that
residual confounding bias is a minor issue in screening
programme evaluations.
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Introduction
Breast cancer screening programmes are now an estab-
lished part of the health care service of many countries [1].
The continuous evaluation of this practice is based on
observational studies, leading to the possibility of con-
founding and self-selection bias.
Toassesstheeffectofscreening,breastcancermortalityin
both screened and not screened women has to be compared;
this can be looked upon as the relative risk (RR, or rate ratio)
ofbreastcancermortality.ConfoundingbiasoftheRRoccurs
when the prevalence of a risk factor (or set of risk factors) for
breast cancer death is imbalanced across the compared
groups.Toadjustfortheconfoundingeffect,theprevalenceof
the risk factor(s) has to become similar in both groups.
Usually age is the only risk factor measured when eval-
uating population-based breast cancer screening pro-
grammes, because information on date of birth and date of
invitation of women is mostly available. Therefore, after
age, residual confounding bias in the screening—mortality
relationremainsthemajorcriticismofobservationalstudies.
This term covers both within-stratum confounding, for
example too-broad age categories, and confounding due to
unmeasured variables [2]. Self-selection bias can be regar-
ded as a special form of residual confounding because par-
ticipation may induce an imbalance in the risk factors for
breast cancer death.
Having accounted for age, we clariﬁed the inﬂuence of
adjustment for residual confounding on the rate ratio of
breast cancer death. We compared the mortality rate in the
screened (Ms) with not screened women (Mns). This results
inan‘apparent’screening—mortality association (RRa)that
is seemingly real, but not necessarily so because of possible
residualconfoundingbias.Thiseffectofscreening,RRa,can
be unravelled in the ‘speciﬁc’ screening effect RRs, and a
‘non-speciﬁc’ effect of the potential confounding fac-
tor(s) C, which is reﬂected in the following formula.
RRa ¼ Ms=Mns
¼ RRs   C
¼ RRs   p1RRc þ 1   p1 ðÞ ½  = p2RRc þ 1   p2 ðÞ ½ 
The quantity C thus represents the effect of the potential
confounder(s) among screened and the not screened
women. The inﬂuence of C depends on the relative risk
of breast cancer death RRc, the proportion p1 of screened
women with the confounder present, and the proportion p2
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formula is based on previous work by Cornﬁeld and
colleagues [3], Schlesselman [4] and Greenland [5].
Suppose, as shown in Fig. 1, that the apparent RRa is
0.50,andariskfactorproducingatwofoldincreaseinriskof
breast cancer death (RRc) is present among 20% (p1) of the
screened group and 50% (p2) of the not screened group.
Then,thenon-speciﬁcpartoftheapparentscreeningeffectis
0.20*2 ? 0.80*1 = 1.20 among the screened women, and
0.50*2 ? 0.50*1 = 1.50 among the not screened women.
The ratio of these non-speciﬁc effects is 1.2/1.5 = 0.80,
which is the inﬂuence of confounding (C) among the
screened and not screened groups. Accordingly, the speciﬁc
RRs will become 0.50/0.80 = 0.63.
In the above calculation we used the cohort approach
and the risk ratio (or rate ratio) as a measure of effect.
However, this same method can be applied when the odds
ratio (OR) is the effect measure. The case—control design
has been increasingly used for the evaluation of screening
programmes [6–12]. In the case—control evaluation, the
odds of having been screened versus not screened in the
case group of breast cancer deaths is compared to the same
odds in the control group of invited women from whom the
cases originate. As such, the OR is the mortality in
screened versus not screened women.
Example based on the Nijmegen Breast Cancer
Screening Programme
As an example, we report on a case–control study con-
ducted within the Nijmegen breast cancer screening
programme which started in 1975. After adjustment for
age, we found that the breast cancer mortality rate in the
screened group was 65% lower than that of the not
screened group: OR = 0.35 and 95% Conﬁdence Interval
(CI) = 0.19–0.64 [12]. What role could residual con-
founding have played in this ﬁnding?
Dense mammographic breast pattern, for which a high
relative risk of 6 has been reported, is a likely candidate for
being treated as a confounding factor [13]. Despite its
strength, this factor is not common in postmenopausal
women. Nevertheless, suppose its prevalence in all screened
women is 5% (p1 = 0.05) in contrast to a supposed 20%
(p2 = 0.20) prevalence in the not screened women, then,
according to the formula, the apparent OR of 0.35 would be
adjustedtoanORof0.56(seealsoFig. 2,leftupperdiagram).
Other risk factors for breast cancer like obesity, socio-
economic status, nulliparity, late age at menopause, early
age at menarche, and family history show a 1.5 to fourfold
relative risk of breast cancer at most [14]. We assume that
the risk magnitude of the factors applies to the incidence
and mortality alike. Fig. 2 illustrates the impact these risk
factors may have as confounders. Panel A shows the
baseline situation of an age-adjusted screening—mortality
OR of 0.35; Panel B is for OR = 0.50 and Panel C for
OR = 0.75. The expected values of the ORs in order of
decreasing magnitude are displayed on the Y-axis in each
ﬁgure: after adjustment for dense breast pattern RRc = 6;
late age at menopause RRc = 4; nulliparity RRc = 2; and
serious overweight RRc = 1.5. The X-axis shows the
proportion (p2) of the not screened population with the
confounding factor. In each ﬁgure, the lines present the OR
adjusted for the confounding factor with p2 ranging from 0
to 0.6, and four different situations of the proportion (p1)
confounder in the screened group: the upper line is for a
p1 = 0.05, then p1 = 0.10, p1 = 0.20 and the lowest line
for a p1 = 0.35. In practice, the deviations between
apparent and adjusted ORs are minor.
Discussion
Previous screening programme evaluations have qualita-
tively discussed the magnitude of residual confounding
bias on their effectiveness estimate [6, 9, 10, 12] or esti-
mated the amount of bias due to self-selection [7, 8, 11].
We present an educated and pragmatic method to quantify
the potential impact of residual confounding, and to de-bias
the comparison of screened with unscreened groups, a
method originally introduced by Cornﬁeld et al. [3]. Our
results demonstrate that residual confounding has a minor
inﬂuence on the observed screening effect.
Closely related to residual confounding is self-selection
bias and healthy screenee bias. The difference between
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Screened 
group: 
p1= 0.2 
Not screened 
group: 
p2= 0.5 
Expected mortality risk in 
not screened group, when p2
isadjusted from 0.5 to 0.2 
Fig. 1 A heuristic device to address residual confounding in the
mortality effect of breast cancer screening. Both arrows on the left
indicatetheobservedbreastcancermortalityriskinthescreenedandnot
screened group, suggesting RRa = 0.50. We assume that a confounder
with a twofold relative risk on breast cancer death (RRc), is present
among 20% (p1) of the women in the screened group and among 50%
(p2) in the not screened group. The arrow on the right indicates the
expected breast cancer mortality risk in the not screened population
whenthepresenceoftheriskfactorinthatgroupisadjustedfrom50%to
20%. The adjusted RRs becomes 0.63 (also demonstrated in Fig. 2)
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123these three biases is subtle; the nuances seem to lie in the
clariﬁcation of deﬁnable confounding factors or a combi-
nation of indeﬁnable confounding factors. Self-selection
into screening may result in an imbalance of a combination
of indeﬁnable risk factors, causing a different background
risk of dying from breast cancer in screened versus not
screened women [15]. Healthy screenee bias may occur
because some women in the not screened group, although
invited for screening, may already have been diagnosed
with cancer, while screened women were not diagnosed
with breast cancer at the time of participation [16]. Both
biases can be regarded as a form of residual confounding
[17] since participation in screening may be correlated with
the baseline risk of dying from breast cancer.
An estimate of the amount of self-selection can be
obtained by calculating the ratio of the breast cancer deaths
among not invited and not screened women [18]. This
calculation is not possible in a steady state situation of
population based screening since there is no uninvited
group. By using the implementation period of screening,
we [11] quantiﬁed a 0.84 lower background risk in not
screened women compared with not yet invited women. A
similar Italian study found a 1.11 higher risk in the not
screened group [8]. Duffy et al. [18] proposed a factor
based on data from the Swedish and Canadian screening
trials, showing a 1.36 higher risk for not screened women.
With these factors, the difference in background risk
between not screened and screened women can be calcu-
lated by taking the percentage uptake in a programme into
account [18]. For instance, if we use Duffy’s factor of 1.36
and if the screening uptake is 80%, which is in accordance
with most European programmes, not screened women
have a 1.42 higher background risk compared with
screened women. This factor actually represents C in our
formula, it is the difference in background risk p1 = 0 and
p2 = 1. In this scenario an apparent OR of 0.35 would be
adjusted to 0.51. However, using our factor of 0.84, not
screened women have a 0.80 lower background risk com-
pared with screened women. In our scenario an apparent
OR of 0.35 would be adjusted to 0.28.
In Cornﬁeld’s original paper [3], he stated that a con-
founding factor completely explains an ‘apparent’ effect
when the effect of confounding in the comparing groups
equals the ‘apparent’ effect, then RRa = C, and RRs = 1.
In our example we applied this method to adjust ORs for
combinations of p2 between 0 and 0.6, and values of
p1 = 0.05, 0.10, 0.20 and 0.35. These values were chosen
based on the expected prevalence of the risk factors in the
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Fig. 2 Diagrams of the
adjustment for residual
confounding in the effectiveness
measurement of breast cancer
service screening. Panel A
shows the baseline situation of
an age-adjusted screening—
mortality OR = 0.35; panel B is
for OR = 0.50 and panel C for
OR = 0.75. From top to
bottom, the ﬁgures represent the
adjusted ORs for confounding
factors with RRc = 6, 4, 2 and
1.5, respectively. The X-axis
displays the proportion (p2)o f
the not screened population with
the confounding factor. The
lines displayed in the ﬁgures
present the adjusted OR for the
confounding factor for p2
ranging from 0.0 to 0.6, and
four different points of
departure for p1 of the screened
population (upper line at
p1 = 0.05, then p1 = 0.10,
p1 = 0.20 and the lowest line
p1 = 0.35). The Y-axis in each
ﬁgure depicts the expected ORs
adjusted for residual
confounding
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123female population, i.e. 5% for mammographic density,
10% for late age at menopause, 20% for nulliparity, and
35% for serious overweight. As, we aimed to challenge the
age-adjusted screening effect, we developed scenarios
where p1 was smaller than p2.
Our calculation does not account for random error or
uncertainties about the relation of risk factors and breast
cancer. It is possible to correct for this by using more
complex techniques based on a Monte Carlo and a
Bayesian approach [19]. However, the aim of this study
was to present a heuristic device to address residual
confounding.
In conclusion, in studies on breast cancer screening the
mortality reduction ranges from 38 to 70% [6–12]. As we
have shown, residual confounding does not have a great
effect on these estimates of screening effectiveness. After
having addressed for age, future breast cancer screening
programme evaluations can ignore residual confounding.
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